Literature DB >> 23629842

The crystal structure of an octapeptide repeat of the prion protein in complex with a Fab fragment of the POM2 antibody.

Mridula Swayampakula1, Pravas Kumar Baral, Adriano Aguzzi, Nat N V Kav, Michael N G James.   

Abstract

Prion diseases are progressive, infectious neurodegenerative disorders caused primarily by the misfolding of the cellular prion protein (PrP(c)) into an insoluble, protease-resistant, aggregated isoform termed PrP(sc). In native conditions, PrP(c) has a structured C-terminal domain and a highly flexible N-terminal domain. A part of this N-terminal domain consists of 4-5 repeats of an unusual glycine-rich, eight amino acids long peptide known as the octapeptide repeat (OR) domain. In this article, we successfully report the first crystal structure of an OR of PrP(c) bound to the Fab fragment of the POM2 antibody. The structure was solved at a resolution of 2.3 Å by molecular replacement. Although several studies have previously predicted a β-turn-like structure of the unbound ORs, our structure shows an extended conformation of the OR when bound to a molecule of the POM2 Fab indicating that the bound Fab disrupts any putative native β turn conformation of the ORs. Encouraging results from several recent studies have shown that administering small molecule ligands or antibodies targeting the OR domain of PrP result in arresting the progress of peripheral prion infections both in ex vivo and in in vivo models. This makes the structural study of the interactions of POM2 Fab with the OR domain very important as it would help us to design smaller and tighter binding OR ligands.
Copyright © 2013 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23629842      PMCID: PMC3719084          DOI: 10.1002/pro.2270

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  50 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code.

Authors:  Frederic A Fellouse; Pierre A Barthelemy; Robert F Kelley; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2005-12-19       Impact factor: 5.469

3.  Prion protein selectively binds copper(II) ions.

Authors:  J Stöckel; J Safar; A C Wallace; F E Cohen; S B Prusiner
Journal:  Biochemistry       Date:  1998-05-19       Impact factor: 3.162

Review 4.  Structure, function and properties of antibody binding sites.

Authors:  I S Mian; A R Bradwell; A J Olson
Journal:  J Mol Biol       Date:  1991-01-05       Impact factor: 5.469

5.  Conformations of the third hypervariable region in the VH domain of immunoglobulins.

Authors:  V Morea; A Tramontano; M Rustici; C Chothia; A M Lesk
Journal:  J Mol Biol       Date:  1998-01-16       Impact factor: 5.469

6.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

7.  Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1.

Authors:  Pravas Kumar Baral; Barbara Wieland; Mridula Swayampakula; Magdalini Polymenidou; Muhammad Hafiz Rahman; Nat N V Kav; Adriano Aguzzi; Michael N G James
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2012-10-18

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 9.  Vaccine approaches to prevent and treat prion infection : progress and challenges.

Authors:  Andreas Müller-Schiffmann; Carsten Korth
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

Review 1.  Transition of the prion protein from a structured cellular form (PrPC ) to the infectious scrapie agent (PrPSc ).

Authors:  Pravas K Baral; Jiang Yin; Adriano Aguzzi; Michael N G James
Journal:  Protein Sci       Date:  2019-10-25       Impact factor: 6.725

Review 2.  Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes.

Authors:  Buyong Ma; Jun Zhao; Ruth Nussinov
Journal:  Biochim Biophys Acta       Date:  2016-06-03

3.  A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity.

Authors:  Marco Bardelli; Karl Frontzek; Luca Simonelli; Simone Hornemann; Mattia Pedotti; Federica Mazzola; Manfredi Carta; Valeria Eckhardt; Rocco D'Antuono; Tommaso Virgilio; Santiago F González; Adriano Aguzzi; Luca Varani
Journal:  PLoS Pathog       Date:  2018-10-01       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.